Insider Selling: Embecta Corp. (NASDAQ:EMBC) Director Sells 3,100 Shares of Stock

Embecta Corp. (NASDAQ:EMBC - Get Free Report) Director Milton Mayo Morris sold 3,100 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $16.38, for a total transaction of $50,778.00. Following the sale, the director now directly owns 36,133 shares of the company's stock, valued at $591,858.54. This represents a 7.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Embecta Trading Up 3.0 %

EMBC stock traded up $0.45 during mid-day trading on Tuesday, reaching $15.30. The company's stock had a trading volume of 460,043 shares, compared to its average volume of 414,782. Embecta Corp. has a 12 month low of $9.93 and a 12 month high of $21.48. The business's 50 day moving average price is $19.12 and its 200 day moving average price is $16.57. The company has a market cap of $889.39 million, a price-to-earnings ratio of 15.30, a price-to-earnings-growth ratio of 0.95 and a beta of 1.20.

Embecta (NASDAQ:EMBC - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. As a group, equities analysts expect that Embecta Corp. will post 2.87 EPS for the current fiscal year.

Embecta Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 14th. Stockholders of record on Friday, February 28th will be given a dividend of $0.15 per share. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 3.92%. Embecta's dividend payout ratio (DPR) is presently 60.00%.

Institutional Trading of Embecta

Several large investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its stake in Embecta by 175.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,216 shares of the company's stock valued at $25,000 after acquiring an additional 774 shares during the period. Quarry LP bought a new position in shares of Embecta in the 3rd quarter worth $30,000. Sterling Capital Management LLC grew its position in Embecta by 796.3% in the 4th quarter. Sterling Capital Management LLC now owns 1,685 shares of the company's stock valued at $35,000 after purchasing an additional 1,497 shares during the period. Copeland Capital Management LLC bought a new stake in Embecta during the 3rd quarter valued at $43,000. Finally, Siemens Fonds Invest GmbH acquired a new position in Embecta during the fourth quarter worth $77,000. 93.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EMBC has been the topic of a number of analyst reports. Morgan Stanley raised shares of Embecta from an "underweight" rating to an "equal weight" rating and upped their price objective for the company from $13.00 to $20.00 in a research note on Monday, December 2nd. BTIG Research raised shares of Embecta from a "neutral" rating to a "buy" rating and set a $26.00 price target on the stock in a research report on Wednesday, November 27th.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.